Video

FDA panels revisit rosiglitazone's cardiovascular safety

Publish date: June 13, 2013
By
Elizabeth Mechcatie

 

The majority of two FDA advisory panels voted to modify or remove the prescribing restrictions on the type 2 diabetes drug rosiglitazone, based on the readjudicated results of a cardiovascular outcomes study, the Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycemia in Diabetes (RECORD) trial. Meeting participants spoke with IMNG Medical Media about the panels' recommendations.

Recommended Reading

In children with hypertension, weight plus race don't add up equally
MDedge Endocrinology
FDA approves ezetimibe-statin combination pill
MDedge Endocrinology
DEA scheduling brings weight-loss drug closer to market
MDedge Endocrinology
Type 2 diabetics often harbor undiagnosed heart failure
MDedge Endocrinology
Risk factors for death in NAFLD patients remain elusive
MDedge Endocrinology
Gastric bypass helps poorly controlled type 2 diabetes
MDedge Endocrinology
FDA panel starts review of rosiglitazone CV data
MDedge Endocrinology
FDA panel supports easing rosiglitazone restrictions
MDedge Endocrinology
Serious hypoglycemic events doubled dementia risk in diabetes
MDedge Endocrinology
Medicare uses more brand-name drugs than does VA
MDedge Endocrinology